Search
brexanolone; allopregnanolone (Zulresso)
Indications:
- post-partum depression [1] (FDA-approved [3])
Dosage:
- administered during a 60-hour intravenous infusion
Adverse effects:
- risk for loss of consciousness/presyncope (4%) [1]
Mechanism of action:
- neuroactive metabolite of progesterone [2]
- barbiturate-like modulator of central GABA receptors
- modifies a range of behaviors, including the stress response
- released in the brain in response to stress,
- quiets the neural system within 30 minutes of escalation
- responsible for the extreme mood swings found in teenagers
General
pregnanolone; 3-alpha-tetrahydroprogesterone; 3-hydroxypreganane-20-one
neurologic agent
Database Correlations
PUBCHEM cid=92786
References
- Young K, Young, Sadoughi S, Sofair A.
FDA Advisers Vote for Approval of Postpartum Depression Treatment.
Physician's First Watch, Nov 5, 2018
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA Briefing Document.
Psychopharmacologic Drugs
Advisory Committee (PDAC) and Drug Safety and Risk Management
(DSaRM)
Advisory Committee Meeting. November 2, 2018 Topic:
New Drug Application 211371/New Drug Application, brexanolone
for the Treatment of Postpartum Depression
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM624643.pdf
- PubChem: 92786
- FDA News Release. March 19, 2019
FDA approves first treatment for post-partum depression.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm